Millipore Sas
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|---|---|
Revenues | 932m | 988m | 1.0b | 1.1b | 1.2b | 1.4b |
% growth | - | 6 % | 4 % | 7 % | 12 % | 12 % |
EBITDA | 171m | 161m | 174m | 197m | 175m | 213m |
% EBITDA margin | 18 % | 16 % | 17 % | 18 % | 14 % | 16 % |
Profit | 101m | 89.9m | 112m | 118m | 104m | 126m |
% profit margin | 11 % | 9 % | 11 % | 11 % | 8 % | 9 % |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$2.0m | Series A | ||
$19.0m | Series B | ||
N/A | Late VC | ||
Total Funding | AUD32.5m |
Related Content
Recent News about Millipore Sas
EditMerck Millipore, operating in the U.S. and Canada as MilliporeSigma, is a leading provider of life science products and services. The company offers a comprehensive range of chemicals and laboratory supplies for various applications, including biosciences, biopharma, food, cosmetics, pharmaceuticals, and more. Merck Millipore serves a diverse clientele, from academic researchers to industrial manufacturers, providing them with innovative solutions that streamline research processes and ensure regulatory compliance. The business model revolves around the sale of high-quality chemicals, laboratory equipment, and specialized services, generating revenue through direct sales and long-term partnerships. The company also offers training programs, webinars, and technical support to enhance customer experience and product utilization.
Keywords: life science, laboratory chemicals, biosciences, biopharma, regulatory compliance, research solutions, industrial applications, training programs, technical support, innovative products.